I'll just make one point briefly on that. I think our colleague from the IP association referenced this briefly. A lot of the history regarding these access-to-medicine sites has to do with threats to IP, compulsory licensing and other measures that then extract concessions around voluntary licensing and other more voluntary measures.
I think that's one potential explanation. If you increase the pressure on industry and you make it clear that you are willing to take more dramatic actions, that is going to create some amount of momentum around voluntary action on behalf of the pharmaceutical industry.